CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IDM Pharma Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IDM Pharma Inc.
9 Parker
Suite 100
Phone: (949) 470-4751p:949 470-4751 Irvine, CA  92618  United States Ticker: IDMI IDMI

This company was Merged or Acquired on 6/24/2009.
This company ceased filing statements with the SEC on 7/6/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
IDM Pharma, Inc. (IDM) is a biopharmaceutical company focused on the development of cancer products that either destroys cancer cells by activating the immune system or prevents tumor recurrence by triggering an adaptive immune response. The Company is developing its principal product candidate, mifamurtide (L-MTP-PE), also called MEPACT in Europe, for the treatment in combination with chemotherapy following surgery of patients with non-metastatic resectable osteosarcoma, or bone cancer. It has received orphan drug designation for mifamurtide in the United States and the European Union for the treatment of osteosarcoma. As of December 31, 2008, the Company also had been developing IDM-2101 for non-small cell lung cancer (NSCLC). IDM-2101 is composed of multiple tumor-specific cytotoxic T-lymphocyte (CTL), epitopes that were selected from tumor-associated antigens. In June 2009, Takeda Pharmaceutical Company Limited completed the acquisition of IDM.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200912/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Treasurer, Secretary, Director IwaakiTaniguchi 6/24/2006 6/24/2006

Business Names
Business Name
IDM Pharma Inc.
IDM-Biotech, Ltd.
IDMI
Immuno-Designed Molecules S.A.

General Information
Number of Employees: 15 (As of 12/31/2008)
Outstanding Shares: 25,278,599 (As of 5/6/2009)
Shareholders: 146
Stock Exchange: NASD
Federal Tax Id: 330245076
Fax Number: (949) 470-6470


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023